EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase IV)Multizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Acceptability and safety of one versus three months of rifapentine and isoniazid to prevent tuberculosis in people exposed in the household or workplace in Brazil: The Ultra-Curto randomized controlled trial

Betina Durovni, Marcelo Cordeiro-Santos, Solange Cesar Cavalcante iD, Renata Spener-Gomes iD, Jamile Garcia iD, Silvia Cohn, Valeria Saraceni iD, Beatriz Kohler, Lawrence H Moulton iD, Alexandra Brito da Souza, Abiye Berihun iD, Mark Marzinke iD und 2 weitere

PLOS Medicine · 10.02.2026 · 23 (2) · e1004758

DOI: 10.1371/journal.pmed.1004758 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS Medicine, online erschienen am 10.02.2026. Verfasst von Betina Durovni und 13 weiteren Autor:innen. Beteiligte Einrichtung: Secretaria Municipal de Saúde do Rio de Janeiro, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: Isoniazid, Rifampin, Antitubercular Agents, Tuberculosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Short-course tuberculosis preventive therapy with isoniazid and rifapentine (HP) is widely recommended, but the acceptability and safety of one month of daily HP (1HP) compared to three months of weekly HP (3HP) is uncertain. We compared treatment with these two regimens in people with a positive latent tuberculosis infection test and without HIV infection. We hypothesized that 1HP would have greater treatment completion and fewer targeted safety events than 3HP. Methods and findings We conducted a Phase 4 randomized trial of 1HP versus 3HP in adolescents and adults without HIV infection with recent tuberculosis exposure and a positive latent tuberculosis infection test in two sites in Brazil. The primary outcomes were successful completion of >90% of medication as ascertained by self-report, pill counts, and pharmacologic monitoring, and safety. Treatment safety was defined as occurrence of Grade > 2 targeted events or discontinuation of treatment for side effects. We randomized 500 individuals to 1HP (249) and 3HP (251); 193 males and 307 females, with a median age of 39 years. Treatment completion was 89.6% for 1HP recipients versus 84.1% for 3HP recipients (site-adjusted risk difference 5.2%, [95% CI: [−0.1%, 11.2%], p = 0.10). Targeted > Grade 2 adverse safety events or treatment discontinuation occurred in 16.1% of 1HP recipients and 10.4% of 3HP recipients (site-adjusted risk difference 6.1%, [95%CI: [−0.04%, 12.3%], p = 0.05). The proportions who discontinued treatment for any side effect were 7.2% for 1HP and 4.4% for 3HP. The risk difference for the primary safety outcome adjusted for site and baseline demographic and clinical covariates was 3.4% (95% CI [−2.3,9.1%], p = 0.24). The trial was not designed to ascertain efficacy.

Conclusion

Both 1HP and 3HP had high rates of treatment success. Participants assigned to 1HP had more targeted safety events, mostly low-grade. Neither regimen was superior to the other. These results will inform global guidelines for tuberculosis preventive therapy. NCT04703075 ( clinicaltrials.gov ).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IsoniazidRifampinAntitubercular AgentsTuberculosisLatent TuberculosisHumansFemaleMaleBrazilAdultAdolescentMiddle AgedYoung AdultWorkplaceFamily CharacteristicsTreatment OutcomeDrug Administration ScheduleTime Factors

Substanzen

IsoniazidRifampinrifapentineAntitubercular Agents

Autor:innen und Institutionen

  • Secretaria Municipal de Saúde do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Fundação de Medicina Tropical "Doutor Heitor Vieira Dourado", Manaus, Brazil.
  • Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Brazil.
  • Pós-Graduação em Saúde e Inovação, Universidade Nilton Lins, Manaus, Amazonas, Brazil.
  • Faculdade de Medicina, Universidade Federal do Amazonas, Manaus, Brazil.
  • Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.

ORCID-Profile: Solange Cesar Cavalcante, Renata Spener-Gomes, Jamile Garcia, Valeria Saraceni, Lawrence H Moulton, Abiye Berihun, Mark Marzinke, Richard E Chaisson

Förderung

  • NIAID NIH HHS
  • Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Durovni, B., Cordeiro-Santos, M., Cavalcante, S. C., Spener-Gomes, R., Garcia, J., Cohn, S., Saraceni, V., Kohler, B., Moulton, L. H., Brito da Souza, A., Berihun, A., Marzinke, M., Chaisson, R. E., & Ultra Curto Study Team (2026). Acceptability and safety of one versus three months of rifapentine and isoniazid to prevent tuberculosis in people exposed in the household or workplace in Brazil: The Ultra-Curto randomized controlled trial. PLOS Medicine, 23(2), e1004758. https://doi.org/10.1371/journal.pmed.1004758

Vancouver

Durovni B, Cordeiro-Santos M, Cavalcante SC, Spener-Gomes R, Garcia J, Cohn S, et al. Acceptability and safety of one versus three months of rifapentine and isoniazid to prevent tuberculosis in people exposed in the household or workplace in Brazil: The Ultra-Curto randomized controlled trial. PLOS Medicine. 2026;23(2):e1004758. doi:10.1371/journal.pmed.1004758

BibTeX
@article{Durovni2026,
  author = {Durovni, Betina and Cordeiro-Santos, Marcelo and Cavalcante, Solange Cesar and Spener-Gomes, Renata and Garcia, Jamile and Cohn, Silvia and Saraceni, Valeria and Kohler, Beatriz and Moulton, Lawrence H and Brito da Souza, Alexandra and Berihun, Abiye and Marzinke, Mark and Chaisson, Richard E and Ultra Curto Study Team, Ultra Curto Study Team},
  title = {Acceptability and safety of one versus three months of rifapentine and isoniazid to prevent tuberculosis in people exposed in the household or workplace in Brazil: The Ultra-Curto randomized controlled trial},
  journal = {PLOS Medicine},
  year = {2026},
  volume = {23},
  number = {2},
  pages = {e1004758},
  doi = {10.1371/journal.pmed.1004758}
}
Kostenlos starten →